Business Wire

New Capability in Vault PromoMats to Speed Packaging Promotional Materials for FDA Submission

9.6.2020 14:03:00 EEST | Business Wire | Press release

Share

Veeva Systems (NYSE: VEEV) today announced at Veeva Summit Online a new capability in Veeva Vault PromoMats to speed the digital submission of promotional materials for accelerated approval products. Vault PromoMats will automatically generate submission-ready forms to simplify packaging promotional materials to send via eCTD (Electronic Common Technical Document) to the U.S. Food and Drug Administration (FDA). Brand marketing teams can reduce time in preparing content in a compliant digital format and getting it ready for FDA submissions.

“Veeva is helping life sciences stay ahead of evolving regulations and accelerate the shift toward digital,” said Pooja Ojala, vice president of commercial content at Veeva. “Veeva Vault PromoMats will allow brand marketing teams to create digital submissions faster and easier, while maintaining compliance with federal requirements.”

Last year the FDA finalized guidance on electronic submission via eCTD for postmarketing and accelerated approval products. Veeva is enabling customers to meet the FDA’s fast-approaching June 2021 deadline that will make it mandatory to submit promotional materials electronically.

Vault PromoMats automates preparing submission-ready content to make it faster and easier for brand marketing teams to package websites, emails, and other content for FDA review. Automatic linking of promotional materials and references simplifies building a package consistent with eCTD data requirements. Templatized forms allow customers to create a binder of relevant documents in the right structure and naming format for faster health authority submission.

In other news today, Veeva announced Veeva Link for KAM, a new solution that gives commercial and medical teams accurate customer data and real-time insights for key account management. Read today’s press release to learn more.

Vault PromoMats is an advanced application that combines digital asset management with medical, legal, and regulatory review to improve global reuse of promotional materials and maintain compliance from content creation through distribution. The new capability to generate submission-ready forms for accelerated approval products is planned for availability in December 2020.

Learn how Vault PromoMats allows brand marketing teams to reduce time and errors when creating digital submissions at Veeva Summit Online, 9-10 June. The event is only open to life sciences industry professionals. Register for the virtual event and on-demand sessions at veeva.com/Summit.

Additional Information

For more on Veeva Vault PromoMats, visit: veeva.com/eu/PromoMats
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants2.3.2026 09:00:00 EET | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the expansion of its 5G RedCap portfolio with the launch of the RM255C-GL for global markets and the RG255C-NA for the North America market, further strengthening its mid-tier 5G offering for worldwide deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301754857/en/ Quectel expands mid-tier 5G portfolio with new RedCap 3GPP release 17 variants As 5G expands further into industrial and IoT domains, the need for solutions that combine strong performance with cost efficiency is becoming increasingly critical. Positioned between high-speed eMBB and narrowband NB-IoT, 5G RedCap (Reduced Capability) has emerged as the ideal technology to address this mid-tier connectivity gap. With a comprehensive product portfolio and global deployment expertise, Quectel enables a seamless transition for mid-speed IoT applications moving toward sca

Thales sets a world first in quantum-safe security for 5G networks2.3.2026 09:00:00 EET | Press release

Quantum computing has the potential to break today’s encryption methods in the future, putting mobile communications, personal data and critical infrastructure at risk. For telecom operators, this is not a distant theoretical issue: 5G networks underpin everything from smartphones and connected vehicles to emergency services, industry and national infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301594505/en/ WORLD FIRST: Thales has successfully demonstrated a world-first innovation that prepares 5G networks for the age of quantum computing, marking a major milestone for the global telecommunications industry. (credit photo 123ref) The challenge is scale. Replacing millions of devices every time security standards evolve is neither practical nor sustainable. The industry needs a new approach. With this demonstration, Thales shows that security can be upgraded remotely and instantly, directly on SIM and eSIM

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera2.3.2026 09:00:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In addition to Priority Review, rusfertide has received Breakthrough Therapy designation, Orphan Drug designation and Fast Track designation from the U.S. FDA. PV is characterized by the overproduction of red blood cells (erythrocytosis), which increases blood viscosity, or thickness, and can result in life threatening thrombotic events. Hematocrit is the ratio of red blood cells to the total amount of blood in the body. Achieving and maintaining controlled hematocrit levels of <45% is the primary tr

NHOA Energy Announces Two Major MACSE Battery Projects2.3.2026 09:00:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, has been awarded two new Battery Energy Storage System (BESS) projects in Italy by a leading independent platform in the renewables and energy transition sector, with a total MACSE-contracted capacity of about 600 MWh and a total power of 90 MW. The two projects, located in Campania and Sardinia, represent NHOA Energy’s first systems awarded under MACSE (Meccanismo di Approvvigionamento di Capacità di Stoccaggio Elettrico), Italy’s new capacity mechanism dedicated to long-duration storage, and a milestone in the company’s growth in the national energy storage market. The projects, financed by a pool of top-tier Italian and international financial institutions, reaffirm NHOA Energy’s centrality as technology supplier and turnkey contractor in the Italian BESS market, built on extensive local and international experience, breadth of resources, intimate understanding of standards and regulation, and awareness of the eme

Airgain and Nextivity Enter Strategic Partnership on Co-developing Next Generation Integrated 4G / 5G Solutions2.3.2026 08:30:00 EET | Press release

Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, and Nextivity, Inc., an industry leader in intelligent cellular coverage solutions, today announced they have entered into a Strategic Partnership Agreement to collaborate on the development of integrated solutions aimed at improving 4G and 5G coverage across challenging indoor and outdoor environments. The agreement establishes a structured framework for Airgain and Nextivity to jointly define and co-develop integrated coverage solutions that leverage Airgain’s Lighthouse™ 5G Intelligent Node platform and Nextivity’s GO family of intelligent repeaters powered by Nextivity’s IntelliBoost® processor to enhance 4G and 5G coverage solutions beyond the walls of a building. Large Market Opportunity & Accelerated Go‑to‑Market Execution Industry demand for intelligent 4G and 5G coverage-extension solutions continues to accelerate as operators, enterprises, and public safety organizations expand network densif

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye